$OPHT $QURE $ONCE $RGNX $SRPT: 4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Date: Monday, April 8th, 2019

Stock(s) mentioned: , , , ,

Source: Zacks.com (https://www.zacks.com)

Summary: Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

Full article address: https://www.zacks.com/stock/news/372303/4-Gene-Therapy-Players-Likely-to-Become-Buyout-Targets-in-2019

Related News:

$OPHT: Ophthotech changes name to IVERIC bio; shares up 7% premarket

$OPHT: Ophthotech Transitions to a Gene Therapy Focused Company …

$RHHBY $NVS $ONCE $OPHT: Ophthotech Gets Rights to Gene Therapy for BEST Disease

$JPM $OPHT: 5 Stocks To Watch For April 12, 2019

$OPHT: Ophthotech in-licenses gene therapies for type of macular …

$OPHT: Ophthotech Obtains Exclusive Global License to AAV Gene Therapy …

$OPHT: Ophthotech (OPHT) Down 2.1% Since Last Earnings Report: Can It Rebound?

$OPHT: Ophthotech Reports Fourth Quarter and Full Year 2018 Financial …

$OPHT: Ophthotech Corporation to Report Fourth Quarter and Full Year …

$OPHT: Ophthotech Announces the Addition of Ophthalmic Industry Leader …

$OPHT: Ophthotech Announces the Addition of Ophthalmic Industry Leader …

Latest News:

$BIIB: Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

$HOG: Harley Davidson second-quarter sales continued to slide as profit falls 19%

$VYM: What If the Fed Does Cut Rates and It’s Already Totally Priced In?

$PEBO: Peoples Bancorp Inc. Declares Quarterly Dividend

$IRDM: Iridium Announces Second-Quarter 2019 Results; Reaffirms 2019 …

$F: Ford to invest another $50 million in its Chicago operations, create …

$PYPL: Why PayPal Stock Could Have a Strong Earnings Season

$UBS: UBS Q2 global wealth profit rises, i-banking fals

$AVY: Avery Dennison tightened FY2019 guidance

$MSFT: Microsoft Caps Off an Amazing 2019. Here’s Why It Can Repeat in …

$HXL: More on Hexcel’s Q2 results; raises FY19 EPS guidance